can you please make ppt for irritants' and counterirritants for physiotherapy pharmacology lecture
counterirritant mechanism of action topical pain relief physiotherapy
capsaicin TRPV1 receptor mechanism substance P pain gate control theory
Irritants Counterirritants PhysioPharma
Presentation · PPTX
| Slide | Content |
|---|---|
| 1 | Title slide |
| 2 | Learning Objectives |
| 3 | Section header — Irritants |
| 4 | Definition & Types of Irritants (primary vs secondary) |
| 5 | Mechanism of Irritant Action (barrier disruption, innate immunity, neurogenic inflammation) |
| 6 | Classification Table — irritants by category with examples & effects |
| 7 | Section header — Counterirritants |
| 8 | Definition, Gate Control Theory, TRPV1/TRPM8 pathways |
| 9 | Classification: Rubefacients → Vesicants → Escharotics |
| 10 | Full drug table: all key agents, mechanisms & indications |
| 11 | Capsaicin deep-dive (TRPV1, Substance P, formulations, Qutenza) |
| 12 | Menthol vs Camphor two-column comparison (TRPM8, TRPV1) |
| 13 | Methyl Salicylate — chemistry, COX inhibition, products, safety |
| 14 | Adverse Effects & Precautions table |
| 15 | Physiotherapy clinical applications (phonophoresis, iontophoresis, patient ed) |
| 16 | Gate Control Theory visual diagram (Aβ/Aδ-C fibres, dorsal horn, SG cell) |
| 17 | Irritants vs Counterirritants — side-by-side comparison |
| 18 | Key Take-Aways (6 numbered points) |
| 19 | Thank You / Discussion slide |
can you please make ppt for plaster,poultices and paste for physiotherapy pharmacology lecture with standard sources
plasters poultices pastes pharmacology physiotherapy definitions mechanisms clinical use
topical drug formulations paste ointment plaster skin layers transdermal delivery
Plasters Poultices Pastes PhysioPharma
Presentation · PPTX
| Slide | Content |
|---|---|
| 1 | Title slide |
| 2 | Learning Objectives |
| 3 | Topical Preparations — Overview & skin penetration factors |
| 4 | Section Header: PLASTERS |
| 5 | Plasters — Definition, composition, and Plaster of Paris chemistry |
| 6 | Classification Table (Adhesive, Medicated, POP, Vesicant, Hydrocolloid, etc.) |
| 7 | Medicated plasters — Transdermal delivery mechanism, occlusion effect |
| 8 | Plaster of Paris — Clinical application in physiotherapy (serial casting, splinting) |
| 9 | Section Header: POULTICES |
| 10 | Poultices — Definition, etymology, history (Edwin Smith Papyrus), modern composition |
| 11 | Mechanisms (moist heat, absorptive/dextranomer, TRPA1 counterirritant, curcumin anti-inflammatory) |
| 12 | Types Table (Kaolin, Mustard, Linseed, Dextranomer, Charcoal, Turmeric, Epsom salt) |
| 13 | Section Header: PASTES |
| 14 | Pastes — Definition, composition (≥20% powder), physical properties |
| 15 | Mechanisms (barrier, zinc astringency, localised drug delivery, compression bandage base) |
| 16 | Key Pastes Table (Lassar's, Zinc+Ichthammol, Coal Tar, Calamine, Salicylic, Antifungal) |
| 17 | Comparison Table: Plasters vs Poultices vs Pastes |
| 18 | Factors affecting percutaneous absorption — visual card layout |
| 19 | PT Clinical Applications (all three types) |
| 20 | Adverse effects & Precautions table |
| 21 | Standard References slide (Fitzpatrick's, Goodman & Gilman's, Roberts & Hedges, British Pharmacopoeia, Lippincott) |
| 22 | Key Take-Aways |
| 23 | Thank You / Discussion |
can you make notes for drug discovery lecture by using standard and updated sources
"drug discovery" AND pipeline
"drug discovery" AND "artificial intelligence" OR "machine learning"
"target identification" AND "drug discovery" AND "genomics"
"clinical trials" AND "drug development" AND phases
Drug Discovery Lecture Notes
Word Document · DOCX
| Section | Content |
|---|---|
| Cover Page | Title, audience, all 6 source references listed |
| 1. Introduction | Drug discovery vs. invention; historical NPs (morphine, penicillin, aspirin); scope & cost data |
| 2. The Pipeline | Full 11-stage table (target ID → Phase IV) with durations; IND application (FDA 21 CFR §312) |
| 3. Target ID & Validation | Genomics/GWAS, scRNA-seq, proteomics, AlphaFold; genetic (CRISPR KO, RNAi) & pharmacological validation; druggability; PROTACs, PPIs, allosteric modulators |
| 4. Experimental Approaches | Medicinal chemistry, SAR, Lipinski's Rule of Five; HTS, DEL; FBDD (X-ray, SPR, NMR); natural products |
| 5. CADD | SBDD (docking, MD, AlphaFold2); LBDD (QSAR, pharmacophore); AI in drug discovery (Zhang et al., Nat Med 2025; generative AI; INX-315, DSP-1181) |
| 6. Preclinical Development | Pharmacology, ADME table, GLP toxicology (acute, chronic, geno-, reproductive, carcinogenicity) |
| 7. Clinical Trials | Phase 0–IV table; RCT design; surrogate vs. clinical endpoints (torcetrapib box); FDA approval process; special designations |
| 8. Biopharmaceuticals | mAbs, ADCs, mRNA, siRNA, CAR-T, bispecifics (table); biosimilars |
| 9. Precision Medicine | Pharmacogenomics (CYP2D6, HER2, EGFR, BRCA); companion diagnostics |
| 10. Policy & Ethics | Patents, Bayh-Dole, Hatch-Waxman, orphan drug; Declaration of Helsinki; AI ethics |
| 11. Emerging Technologies | 10-item table: CRISPR, organoids, PROTACs, molecular glues, DEL, generative AI, mRNA, CAR-T, Casgevy |
| 12. Summary | Attrition/success rate table; key concept box |
| 13. References | 20 numbered references — Goodman & Gilman, Lippincott, Rang & Dale, FDA, BP, + 14 PubMed citations (2022–2025) with PMIDs |